Group B Strep Meningitis Still Has Poor Outcomes in Infants

Now Rare, Infection Causes Death or Severe Disability in One-Fourth of Cases, Reports Pediatrics Infectious Disease Journal

Newswise — Although now less frequent because of preventive antibiotics, meningitis caused by group B streptococcal (GBS) bacteria is still a serious illness causing a high rate of death and severe complications in infants, reports a study in the November issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

"Despite advances in intensive care, 26 percent of term and near-term infants with GBS meningitis die or have neurologic impairment at hospital discharge," concludes the study by Dr. Fatma Levent and colleagues of Baylor College of Medicine and Texas Children's Hospital, Houston.

Now Less Common, GBS Meningitis in Infants Is Still Very SeriousA review of hospital records from 1998 to 2006 identified 53 full-term infants with GBS meningitis. The disease was considered "early onset" in six infants who became ill during the first week after birth, and "late onset" in 47 infants who became ill after the first week.

Meningitis caused by GBS was once a fairly common disease of newborns, often transmitted at birth from mothers who are colonized by the GBS bacteria.(Being "colonized" means that the bacteria are present, but aren't causing any disease in the mother.) Beginning in the 1990s, hospitals started giving preventive antibiotics during the last weeks of pregnancy (intrapartum antibiotic prophylaxis) to mothers colonized with GBS.

Follow-up data on the 53 infants showed that GBS meningitis is still a very serious infection. Three of the infants died, and another eleven were left with neurological impairment (such as seizures or muscle spasticity). Thus more than one-fourth of infants with GBS meningitis died or had severe complications. The risk was higher for infants with early-onset versus late-onset GBS meningitis: 50 versus 17 percent.

Certain factors were associated with an increased risk of such adverse outcomes. Infants who were having seizures by the time they were admitted to the hospital were at particularly high risk of death or neurological impairment.

With the introduction of intrapartum antibiotic prophylaxis, the rate of early-onset GBS meningitis has declined sharply—by at least 80 percent from 1993 to 2008, according to one study. Preventive antibiotics don't affect the risk of late-onset GBS meningitis, which has actually become slightly more common.

"Despite a decline in early-onset infant GBS disease in recent years, the diagnosis of GBS meningitis...continues to carry a high risk for an adverse outcome," the researchers write. They suspect that the true impact of the disease is even greater, as some infants who survive with apparently normal neurological function may experience subtle developmental delays or learning disabilities later in childhood.

Dr. Levent and colleagues call for further studies to assess the long-term outcomes of infants with GBS meningitis. "Even more importantly," they write, "methods to prevent these infections should be a public health priority."

About The Pediatric Infectious Disease JournalThe Pediatric Infectious Disease Journal® (http://www.pidj.com) is a peer-reviewed, multidisciplinary journal directed to physicians and other health care professionals who manage infectious diseases of childhood. The journal delivers the latest insights on all aspects of infectious disease in children, from state-of-art diagnostic techniques to the most effective drug therapies and other essential treatment protocols. The Pediatric Infectious Disease Journal is official journal of the Pediatric Infectious Diseases Society and the European Society for Paediatric Infectious Diseases.

About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.

LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.